Evidence map›Paper›PMID 32803686›Full record

ArticleDaru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences2020

The synergistic anticancer effects of ReoT3D, CPT-11, and BBI608 on murine colorectal cancer cells.

Abouzar Babaei, Hoorieh Soleimanjahi, Masoud Soleimani, Ehsan Arefian

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. Microbiota-Host-Irinotecan Axis: A New Insight Toward Irinotecan Chemotherapy.Frontiers in cellular and infection microbiology · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Abouzar BabaeiDepartment of Virology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran.ORCID https://orcid.org/0000-0002-1680-5730
Hoorieh SoleimanjahiDepartment of Virology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran. soleim_h@modares.ac.ir.ORCID https://orcid.org/0000-0003-1931-7801
Masoud SoleimaniDepartment of Hematology and cell therapy, Tarbiat Modares University, Tehran, Iran.ORCID https://orcid.org/0000-0003-1972-7771
Ehsan ArefianDepartment of Microbiology, School of Biology, College of Science, University of Tehran, Tehran, Iran.ORCID https://orcid.org/0000-0002-0758-4710
Tarbiat Modares University · IRUniversity of Tehran · IR

Funding

National Institute for Medical Research Development 957970Tarbiat Modares University Med-76015
6 · The paper itself

Abstract

backgroundMany types of oncolytic viruses (OVs) were enrolled in clinical trials. Recently, an OV named Talimogene laherparepvec approved for the treatment of melanoma. This achievement highlighted the clinical application of OVs. Scientists focus on using these anticancer agents in combination with the current or/and new anticancer chemotherapeutics. They aim to increase the oncolytic effect of a new approach for the treatment of cancer cells.

objectivesThe present study aimed to assess the anticancer impacts of ReoT3D, irinotecan (CPT-11), and napabucasin (BBI608) against murine colorectal cancer cells (CT26). They are assessed alone and in combination with each other.

methodsHere, oncolytic reovirus was propagated and titrated. Then MTT assay was carried out to assess the toxicity of this OV and chemotherapeutics effect on CT26 cells. The anticancer effects of ReoT3D, CPT-11, and BBI608, alone and simultaneously, on CT26 cell line, were assessed by the induction of apoptosis, cell cycle arrest, colony-forming, migration, and real-time PCR experiments.

resultsAlone treatment with ReoT3D, CPT-11, and BBI608 led to effectively inducing of apoptosis, cell cycle arrest, and apoptotic genes expression level and significantly reduce of colony-forming, migration, and anti-apoptotic genes expression rate. Importantly, the maximum anticancer effect against CT26 cell line was seen upon combination ReoT3D, CPT-11, and BBI608 treatment.

conclusionThe present study highlights that combination of ReoT3D, CPT-11, and BBI560 showed synergistic anticancer activity against CT26 cell line. This modality might be considered as a new approach against colorectal cancer (CRC) in the in vivo and clinical trial investigations.

Indexed as

AnimalsApoptosis Regulatory ProteinsBenzofuransBiological ProductsCell Cycle ProteinsCell LineCell Line, TumorCell MovementCell ProliferationCell SurvivalColorectal NeoplasmsCombined Modality TherapyDrug SynergismGene Expression Regulation, NeoplasticHerpesvirus 1, HumanIrinotecanApoptosis Regulatory ProteinsBenzofuransBiological ProductsCell Cycle ProteinsHras protein, mouseIrinotecannapabucasinNaphthoquinonesProto-Oncogene Proteins p21(ras)Stat3 protein, mouseSTAT3 Transcription Factortalimogene laherparepvecColorectal cancerCombinationIrinotecanNapabucasinOncolytic reovirus

Identifiers

PMID32803686
PMCPMC7704878
OpenAlexW3049183347

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.